Free Trial

Zoetis (ZTS) Stock Forecast & Price Target

Zoetis logo
$175.67 +0.11 (+0.06%)
(As of 11/20/2024 ET)

Zoetis - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
10

Based on 10 Wall Street analysts who have issued ratings for Zoetis in the last 12 months, the stock has a consensus rating of "Buy." Out of the 10 analysts, 9 have given a buy rating, and 1 has given a strong buy rating for ZTS.

Consensus Price Target

$221.44
26.06% Upside
According to the 10 analysts' twelve-month price targets for Zoetis, the average price target is $221.44. The highest price target for ZTS is $237.00, while the lowest price target for ZTS is $196.00. The average price target represents a forecasted upside of 26.06% from the current price of $175.67.
Get the Latest News and Ratings for ZTS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Zoetis and its competitors.

Sign Up

ZTS Analyst Ratings Over Time

TypeCurrent Forecast
11/22/23 to 11/21/24
1 Month Ago
10/23/23 to 10/22/24
3 Months Ago
8/24/23 to 8/23/24
1 Year Ago
11/22/22 to 11/22/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
9 Buy rating(s)
8 Buy rating(s)
6 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$221.44$221.44$217.11$216.29
Forecasted Upside26.06% Upside16.84% Upside19.98% Upside20.59% Upside
Consensus Rating
Buy
Buy
Buy
Buy

ZTS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ZTS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Zoetis Stock vs. The Competition

TypeZoetisMedical CompaniesS&P 500
Consensus Rating Score
3.10
2.80
2.50
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside26.06% Upside26,906.43% Upside9.81% Upside
News Sentiment Rating
Positive News

See Recent ZTS News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/11/2024JPMorgan Chase & Co.
3 of 5 stars
 Boost TargetOverweight ➝ Overweight$225.00 ➝ $230.00+20.70%
9/18/2024Stifel Nicolaus
4 of 5 stars
 Boost TargetBuy ➝ Buy$200.00 ➝ $210.00+7.29%
8/14/2024Piper Sandler
2 of 5 stars
 Boost TargetOverweight ➝ Overweight$195.00 ➝ $210.00+14.14%
8/12/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Massaro
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$220.00 ➝ $225.00+22.75%
8/9/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Hellweg
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/8/2024HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$230.00 ➝ $225.00+36.80%
5/6/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$223.00 ➝ $196.00+17.58%
4/23/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$260.00 ➝ $230.00+54.58%
12/19/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$230.00+16.03%
12/7/2023BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$237.00+30.22%
4/11/2023Bank Of America (Bofa)
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$180.00 ➝ $200.00+16.74%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 04:46 AM ET.


Should I Buy Zoetis Stock? ZTS Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, November 4, 2024. Please send any questions or comments about these Zoetis pros and cons to contact@marketbeat.com.

Zoetis
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Zoetis Inc.:

  • Zoetis Inc. reported strong earnings results, beating analysts' consensus estimates, indicating a healthy financial performance.
  • The company has a high return on equity of 50.67%, showcasing efficient utilization of shareholder equity to generate profits.
  • Recent Wall Street analyst reports have given Zoetis Inc. positive ratings, with price targets indicating potential stock price growth.
  • Institutional investors, such as Hsbc Holdings PLC and Czech National Bank, have been increasing their stakes in Zoetis Inc., reflecting confidence in the company's future prospects.
  • Zoetis Inc. has a strong market capitalization of $89.65 billion, indicating its position as a significant player in the industry.

Zoetis
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Zoetis Inc. for these reasons:

  • Zoetis Inc.'s stock price has experienced fluctuations, which may introduce volatility and uncertainty for investors.
  • The company's price-to-earnings ratio of 37.86 suggests that the stock may be relatively expensive compared to industry peers, potentially limiting immediate upside potential.
  • While Zoetis Inc. has shown revenue growth, the price-to-earnings-growth ratio of 2.98 indicates that the stock may be overvalued based on its growth prospects.
  • Debt-to-equity ratio of 1.32 may raise concerns about the company's leverage and financial risk, impacting investor confidence.
  • Recent trading volumes and stock price movements suggest potential market sentiment shifts that could affect short-term stock performance.

ZTS Forecast - Frequently Asked Questions

According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Zoetis is $221.44, with a high forecast of $237.00 and a low forecast of $196.00.

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last year. There are currently 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ZTS shares.

According to analysts, Zoetis's stock has a predicted upside of 26.06% based on their 12-month stock forecasts.

Zoetis has been rated by research analysts at JPMorgan Chase & Co., and Stifel Nicolaus in the past 90 days.

Analysts like Zoetis more than other "medical" companies. The consensus rating for Zoetis is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ZTS compares to other companies.


This page (NYSE:ZTS) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners